Performance-enhancing peptides are increasingly popular among fitness enthusiasts and biohackers, despite limited human ...
UCB, a global biopharmaceutical company, today announced positive topline data from the BE BOLD trial assessing BIMZELX® (bimekizumab) versus SKYRIZI® (risankizumab) in adults with active psoriatic ...
TUBERCULOSIS AWARENESS. Department of Health - Cordillera focal person for Tuberculosis (TB) program Geeny Austria explains the symptoms of TB, during a virtual briefing on Wednesday (March 11, 2026).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results